SIGA Technologies, Inc.

NASDAQ:SIGA

Drug Manufacturers - Specialty & Generic

Healthcare
$2.80 -0.36%

-$0.02 today

Market cap
$201.19M
Beta
0.85
P/E (TTM)
15.2
EPS (TTM)
$0.28
Dividend yield
13.97%
52W Low $4.10High $9.62

Volume 0.37M

Average 0.61M

SIGA Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

SIGA Technologies, Inc.NASDAQ: SIGA

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of $149.95K rose 10.8% year over year, ahead of the +7.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 2.3% from the prior quarter. Over 3 fiscal years it compounded at +2.8% a year.

Context

  • Depreciation & amortization amounted to 0.6% of revenue in FY2025, up 0.2 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +10.8% holds above the trailing-twelve-month pace of +7.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$149.95K+2.3% QoQ
Last fiscal yearDec 2025
$562.61K+4.5% YoY
LTMMar 2026
$577.25K+7.8% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.8%——
1 year+4.5%——
3-year CAGR+2.8%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
562.61K USD
Year-over-year change
+4.5%
4-year CAGR
+1.9%

Depreciation & Amortization vs competitors

How SIGA compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +7.8% is the 4th highest of 10, against a peer median of -1.0%.
  • Depreciation & amortization amounts to 0.6% of revenue for SIGA, versus a peer median of 4.4%.
SIGA Competitors
Depreciation & Amortization for SIGA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EBSEmergent BioSolutions Inc.LTM Mar 2026$93.9M USD-11.7%-12.6%13.9%
SNDLSNDL Inc.LTM Mar 2026CA$56.2M CAD-0.2%+5.9%6.0%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$30.95M USD+45.2%+35.9%6.0%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$2.41M USD-1.0%+34.3%0.8%
DRIODarioHealth Corp.LTM Mar 2026$2.04M USD-72.3%-15.6%9.6%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$1.5M USD+328.5%-40.6%0.4%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$1.03M USD-39.0%-38.3%2.9%
SIGASIGA Technologies, Inc.LTM Mar 2026$577.25K USD+7.8%+2.8%0.6%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$522K USD-19.7%-38.8%1.0%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$481K USD+11.1%-33.4%—
Peer median (excluding SIGA) —-1.0%-15.6%4.4%

Competitors are the stored peer set for SIGA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income69.45M33.9M68.07M59.21M23.28M
Depreciation & Amortization522.37K517.64K538.29K538.42K562.61K
Deferred Income Tax121.45K(3.83M)(4.8M)193.42K6.43M
Stock-Based Compensation1.27M1.78M2.05M3.64M3.68M
Change in Working Capital(60.37M)9.44M28.36M(4.69M)8.26M
Accounts Receivables(80.31M)38.24M24.28M(35.18K)17.9M
Inventory136.37K(19.96M)(25.52M)15.34M(846.31K)
Accounts Payables1.47M2.07M2M(5.74M)(578.64K)
Other Working Capital18.34M(10.91M)27.61M(14.26M)(8.22M)
Other Non-Cash Items501K(199.19K)579.24K(10.13M)1.26M
Operating Cash Flow11.49M41.61M94.8M48.76M43.47M
Capital Expenditures(50.62K)0(21.69K)(42.45K)(355.01K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(50.62K)0(21.69K)(42.45K)(355.01K)
Debt Repayment00000
Common Stock Issued00000
Common Stock Repurchased(26.02M)(13.01M)(11.07M)(799.9K)0
Dividends Paid0(32.94M)(32.14M)(42.67M)(43.12M)
Other Financing Activities(173.92K)(12.53K)(214.79K)0(433.76K)
Financing Cash Flow(26.2M)(45.96M)(43.42M)(43.46M)(43.55M)
Effect of Forex Changes00000
Net Change in Cash(14.75M)(4.35M)51.36M5.25M(433.85K)
Free Cash Flow11.44M41.61M94.78M48.72M43.12M

SIGA Technologies, Inc.

NASDAQ:SIGA

Intrinsic Alpha fair value

Locked

Current Price

$2.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.